1
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Early antibody treatment, inflammation, and risk of post-COVID conditions

      research-article
      1 , , 2 , 3 , 4 , 5 , 6 , 1 , 5 , 4 , 7 , 8 , 1 , 5 , 1 , 1 , 9 , 10 , 11 , 12 , 13 , 7 , 14 , 15 , 16 , 17 , 18 , 19 , 5 , 7 , 20 , 21 , 22 , 23 , 24 , 24 , 24 , 24 , 25 , 25 , 4 , 24 , 25 , 4 , , 25 , on behalf of the CSSC-004 Consortium
      mBio
      American Society for Microbiology
      COVID-19, COVID-19 serotherapy, post-COVID condition (PCC), post-acute sequelae of COVID (PASC), interleukin-6, cytokines, chemokines

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate logistic regression models. One third of the 882 participants had day 90 PCC symptoms, with fatigue (14.5%) and anosmia (14.5%) being most common. Cytokine levels decreased from baseline to day 90. In a multivariable analysis, female sex (adjusted odds ratio [AOR] = 2.69 [1.93–3.81]), older age (AOR = 1.32 [1.17–1.50]), and elevated baseline levels of IL-6 (AOR = 1.59 [1.02–2.47]) were independently associated with development of PCC. Those who received early CCP treatment (≤5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC.

          IMPORTANCE

          Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          An inflammatory cytokine signature predicts COVID-19 severity and survival

          Several studies have revealed that the hyper-inflammatory response induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major cause of disease severity and death. However, predictive biomarkers of pathogenic inflammation to help guide targetable immune pathways are critically lacking. We implemented a rapid multiplex cytokine assay to measure serum interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α and IL-1β in hospitalized patients with coronavirus disease 2019 (COVID-19) upon admission to the Mount Sinai Health System in New York. Patients (n = 1,484) were followed up to 41 d after admission (median, 8 d), and clinical information, laboratory test results and patient outcomes were collected. We found that high serum IL-6, IL-8 and TNF-α levels at the time of hospitalization were strong and independent predictors of patient survival (P < 0.0001, P = 0.0205 and P = 0.0140, respectively). Notably, when adjusting for disease severity, common laboratory inflammation markers, hypoxia and other vitals, demographics, and a range of comorbidities, IL-6 and TNF-α serum levels remained independent and significant predictors of disease severity and death. These findings were validated in a second cohort of patients (n = 231). We propose that serum IL-6 and TNF-α levels should be considered in the management and treatment of patients with COVID-19 to stratify prospective clinical trials, guide resource allocation and inform therapeutic options.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A clinical case definition of post-COVID-19 condition by a Delphi consensus

            People with COVID-19 might have sustained postinfection sequelae. Known by a variety of names, including long COVID or long-haul COVID, and listed in the ICD-10 classification as post-COVID-19 condition since September, 2020, this occurrence is variable in its expression and its impact. The absence of a globally standardised and agreed-upon definition hampers progress in characterisation of its epidemiology and the development of candidate treatments. In a WHO-led Delphi process, we engaged with an international panel of 265 patients, clinicians, researchers, and WHO staff to develop a consensus definition for this condition. 14 domains and 45 items were evaluated in two rounds of the Delphi process to create a final consensus definition for adults: post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include, but are not limited to, fatigue, shortness of breath, and cognitive dysfunction, and generally have an impact on everyday functioning. Symptoms might be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms might also fluctuate or relapse over time. A separate definition might be applicable for children. Although the consensus definition is likely to change as knowledge increases, this common framework provides a foundation for ongoing and future studies of epidemiology, risk factors, clinical characteristics, and therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

              ABSTRACT Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, it has rapidly spread across many other countries. While the majority of patients were considered mild, critically ill patients involving respiratory failure and multiple organ dysfunction syndrome are not uncommon, which could result death. We hypothesized that cytokine storm is associated with severe outcome. We enrolled 102 COVID-19 patients who were admitted to Renmin Hospital (Wuhan, China). All patients were classified into moderate, severe and critical groups according to their symptoms. 45 control samples of healthy volunteers were also included. Inflammatory cytokines and C-Reactive Protein (CRP) profiles of serum samples were analyzed by specific immunoassays. Results showed that COVID-19 patients have higher serum level of cytokines (TNF-α, IFN-γ, IL-2, IL-4, IL-6 and IL-10) and CRP than control individuals. Within COVID-19 patients, serum IL-6 and IL-10 levels are significantly higher in critical group (n = 17) than in moderate (n = 42) and severe (n = 43) group. The levels of IL-10 is positively correlated with CRP amount (r = 0.41, P < 0.01). Using univariate logistic regression analysis, IL-6 and IL-10 are found to be predictive of disease severity and receiver operating curve analysis could further confirm this result (AUC = 0.841, 0.822 respectively). Our result indicated higher levels of cytokine storm is associated with more severe disease development. Among them, IL-6 and IL-10 can be used as predictors for fast diagnosis of patients with higher risk of disease deterioration. Given the high levels of cytokines induced by SARS-CoV-2, treatment to reduce inflammation-related lung damage is critical.
                Bookmark

                Author and article information

                Contributors
                Role: ConceptualizationRole: SupervisionRole: Writing – original draftRole: Project administrationRole: Writing – review and editing
                Role: Writing – review and editingRole: MethodologyRole: SupervisionRole: Project administration
                Role: Writing – review and editingRole: MethodologyRole: Project administrationRole: Supervision
                Role: Formal analysisRole: MethodologyRole: Writing – original draftRole: Writing – review and editing
                Role: MethodologyRole: Writing – review and editing
                Role: Formal analysisRole: MethodologyRole: Writing – review and editing
                Role: Data curationRole: Writing – review and editing
                Role: MethodologyRole: Writing – review and editing
                Role: Data curationRole: Writing – review and editing
                Role: Data curationRole: Writing – review and editing
                Role: Data curationRole: Writing – review and editing
                Role: Data curationRole: Writing – review and editing
                Role: Formal analysisRole: MethodologyRole: Writing – review and editing
                Role: Data curationRole: Writing – review and editing
                Role: Writing – review and editingRole: Project administrationRole: Supervision
                Role: Writing – review and editingRole: Project administrationRole: Supervision
                Role: Writing – review and editingRole: Project administrationRole: Supervision
                Role: Writing – review and editingRole: Project administrationRole: Supervision
                Role: Writing – review and editingRole: Project administrationRole: Supervision
                Role: Writing – review and editingRole: Project administrationRole: Supervision
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: MethodologyRole: Writing – review and editingRole: Project administrationRole: Supervision
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: Project administrationRole: SupervisionRole: Writing – review and editing
                Role: ConceptualizationRole: Funding acquisitionRole: SupervisionRole: Writing – review and editingRole: Project administration
                Role: ConceptualizationRole: Funding acquisitionRole: Project administrationRole: SupervisionRole: Writing – original draftRole: Writing – review and editing
                Role: ConceptualizationRole: Funding acquisitionRole: SupervisionRole: Writing – review and editingRole: Project administrationRole: Writing – original draft
                Role: Editor
                Journal
                mBio
                mBio
                mBio
                mBio
                American Society for Microbiology (1752 N St., N.W., Washington, DC )
                2150-7511
                Sep-Oct 2023
                19 September 2023
                19 September 2023
                : 14
                : 5
                : e00618-23
                Affiliations
                [1 ] Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine; , Baltimore, Maryland, USA
                [2 ] Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham; , Birmingham, Alabama, USA
                [3 ] Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine; , Houston, Texas, USA
                [4 ] Department of Pathology, Johns Hopkins University School of Medicine; , Baltimore, Maryland, USA
                [5 ] Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health; , Baltimore, Maryland, USA
                [6 ] Department of Epidemiology, University of Colorado, Anschutz Medical Campus; , Aurora, Colorado, USA
                [7 ] Departement of International Health, Johns Hopkins University Bloomberg School of Public Health; , Baltimore, Maryland, USA
                [8 ] Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH; , Baltimore, Maryland, USA
                [9 ] Department of Medicine, Division of Infectious Diseases, University of California; , San Diego, California, USA
                [10 ] Department of Medicine, Division of Infectious Diseases, University of California; , Los Angeles, California, USA
                [11 ] Department of Medicine, Division of Hematology and Oncology, University of Massachusetts Chan Medical School; , Worchester, Massachusetts, USA
                [12 ] Luminis Health; , Annapolis, Maryland, USA
                [13 ] Department of Medicine, Division of Infectious Diseases, University of California; , Irvine, California, USA
                [14 ] Department of Medicine, Division of Infectious Diseases, University of Cincinnati; , Cincinnati, Ohio, USA
                [15 ] Department of Emergency Medicine, Rhode Island Hospital Warren Alpert Medical School of Brown University; , Providence, Rhode Island, USA
                [16 ] Department of Medicine, Division of Allergy and Immunology, Northshore University Health System; , Evanston, Illinois, USA
                [17 ] Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center; , Houston, Texas, USA
                [18 ] Department of Emergency Medicine, Wayne State University; , Detroit, Michigan, USA
                [19 ] Department of Pathology, University of New Mexico; , Albuquerque, New Mexico, USA
                [20 ] Department of Medicine, Division of Infectious Diseases, University of Miami, Miller School of Medicine; , Miami, Florida, USA
                [21 ] Department of Pathology, Northshore University Health System; , Evanston, Illinois, USA
                [22 ] Division of Infectious Diseases, Medstar Georgetown University Hospital; , Washington, DC, USA
                [23 ] Department of Medicine, Division of Infectious Diseases, Mayo Clinic Hospital; , Phoenix, Arizona, USA
                [24 ] Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine; , Baltimore, Maryland, USA
                [25 ] Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health; , Baltimore, Maryland, USA
                Griffith University-Gold Coast Campus; , Gold Coast, Australia
                Author notes
                Address correspondence to Kelly A. Gebo, kgebo@ 123456jhmi.edu
                Address correspondence to Aaron A. R. Tobian, atobian1@ 123456jhmi.edu

                Aaron A. R. Tobian and David J. Sullivan are shared senior authors.

                See Acknowledgments for conflicts of interest.

                Author information
                https://orcid.org/0000-0002-3317-7449
                https://orcid.org/0000-0002-6429-4760
                https://orcid.org/0000-0003-2174-5004
                https://orcid.org/0000-0001-6687-6775
                https://orcid.org/0000-0001-8512-8326
                https://orcid.org/0000-0002-0730-5224
                https://orcid.org/0000-0003-3248-1761
                https://orcid.org/0000-0001-8181-9517
                https://orcid.org/0000-0002-9402-9167
                https://orcid.org/0000-0002-0517-3766
                https://orcid.org/0000-0003-0319-0578
                Article
                00618-23 mbio.00618-23
                10.1128/mbio.00618-23
                10653913
                37724870
                b26b1699-0a95-49b6-95b3-77a802257a05

                This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

                History
                : 13 March 2023
                : 02 June 2023
                Page count
                supplementary-material: 1, authors: 43, Figures: 3, Tables: 4, References: 44, Pages: 16, Words: 9333
                Funding
                Funded by: U.S. Department of Defense (DOD);
                Award ID: W911QY2090012
                Award Recipient :
                Funded by: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID);
                Award ID: R01AI152078
                Award Recipient :
                Funded by: HHS | NIH | National Institute on Drug Abuse (NIDA);
                Award ID: F31DA054849
                Award Recipient :
                Funded by: HHS | NIH | National Center for Advancing Translational Sciences (NCATS);
                Award ID: U24TR001609
                Award Recipient :
                Funded by: HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);
                Award ID: R01DK131926
                Award Recipient :
                Funded by: HHS | NIH | National Institute of Allergy and Infectious Diseases Division of Intramural Research;
                Award Recipient :
                Funded by: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID);
                Award ID: R01AI120938S1
                Award Recipient :
                Categories
                Research Article
                editors-pick, Editor’s Pick
                epidemiology, Epidemiology
                Custom metadata
                September/October 2023

                Life sciences
                covid-19,covid-19 serotherapy,post-covid condition (pcc),post-acute sequelae of covid (pasc),interleukin-6,cytokines,chemokines

                Comments

                Comment on this article